Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915

NOVO NORDISK AS

(NOVO B)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk : FDA Approves Novo Nordisk's Rybelsus Diabetes Tablets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/20/2019 | 11:17am EDT

By Chris Wack

The U.S. Food and Drug Administration said Friday it approved Novo Nordisk's (NVO) Rybelsus semaglutide oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.

The FDA said Rybelsus is the first glucagon-like peptide, or GLP-1, receptor protein treatment approved for use in the U.S. that doesn't need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.

The FDA said like GLP-1, Rybelsus slows digestion, prevents the liver from making too much sugar, and helps the pancreas produce more insulin when needed.

Novo Nordisk said it is working with health insurance providers with a goal of ensuring broad insurance coverage and patient access to the product. A savings card program will be available at the time of launch for eligible commercially-insured patients to keep out of pocket costs down to as little as $10 a month.

The FDA is still reviewing Novo Nordisk's new drug application for Rybelsus, seeking an additional indication to reduce the risk of major adverse cardiovascular events such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. A decision is expected in the first quarter of 2020.

Novo Nordisk said Rybelsus is currently under review by several regulatory agencies around the world, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency.

Write to Chris Wack at chris.wack@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVO NORDISK AS
08:26aNOVO NORDISK : A/S – Share repurchase programme
PU
08:26aNOVO NORDISK : Disclosure of transaction data
PU
10/09NOVO NORDISK : K-P CM inaugurates mobile diabetic clinic
AQ
10/08NOVO NORDISK : MIT - New capsule can orally deliver drugs that usually have to b..
AQ
10/07NOVO NORDISK : Disclosure of transaction data
PU
10/07NOVO NORDISK A/S : – Share repurchase programme
AQ
10/04UNIVERSITY OF BIRMINGHAM : New partnership aims to identify new disease mechanis..
AQ
10/04EUROPE MARKETS: Defensive Plays Nudge European Stocks Higher As Key Jobs Data..
DJ
10/02NOVO NORDISK : and Noom to partner around digital health solutions to help peopl..
AQ
09/30NOVO NORDISK : A/S – Share repurchase programme
PU
More news
Financials (DKK)
Sales 2019 121 B
EBIT 2019 52 731 M
Net income 2019 39 094 M
Finance 2019 11 374 M
Yield 2019 2,38%
P/E ratio 2019 21,6x
P/E ratio 2020 18,7x
EV / Sales2019 6,84x
EV / Sales2020 6,41x
Capitalization 838 B
Chart NOVO NORDISK AS
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 367,82  DKK
Last Close Price 354,45  DKK
Spread / Highest target 27,0%
Spread / Average Target 3,77%
Spread / Lowest Target -37,1%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS17.25%121 422
JOHNSON & JOHNSON0.01%346 602
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287